|
1.
|
Baquero G, Banchs JE, Naccarelli GV, Gonzalez M, Wolbrette DL. Cardiogenic shock as the initial presentation of systemic lupus erythematosus: a case report and review of the literature. Congest Heart Fail. 2012 Nov; 18(6):337-41.
|
|
|
|
|
2.
|
Naccarelli GV, Wolbrette DL, Levin V, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol. 2011; 5:103-19.
|
|
|
|
|
3.
|
Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies. J Cardiovasc Electrophysiol. 2012 Mar; 23(3):296-301.
|
|
|
|
|
4.
|
Li X, Shaffer ML, Rodríguez-Colón SM, He F, Bixler EO, Vgontzas AN, Wolbrette DL, Wu C, Ball RW, Liao D. Systemic inflammation and circadian rhythm of cardiac autonomic modulation. Auton Neurosci. 2011 Jul 5; 162(1-2):72-6.
|
|
|
|
|
5.
|
Li X, Shaffer ML, Rodriguez-Colon S, He F, Wolbrette DL, Alagona P, Wu C, Liao D. The circadian pattern of cardiac autonomic modulation in a middle-aged population. Clin Auton Res. 2011 Jun; 21(3):143-50.
|
|
|
|
|
6.
|
Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission. J Cardiovasc Pharmacol Ther. 2010 Dec; 15(4 Suppl):24S-30S.
|
|
|
|
|
7.
|
Wolbrette D, Gonzalez M, Samii S, Banchs J, Penny-Peterson E, Naccarelli G. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. Vasc Health Risk Manag. 2010; 6:517-23.
|
|
|
|
|
8.
|
He F, Shaffer ML, Li X, Rodriguez-Colon S, Wolbrette DL, Williams R, Cascio WE, Liao D. Individual-level PM2.5 exposure and the time course of impaired heart rate variability: the APACR Study. J Expo Sci Environ Epidemiol. 2011 Jan-Feb; 21(1):65-73.
|
|
|
|
|
9.
|
Liao D, Shaffer ML, Rodriguez-Colon S, He F, Li X, Wolbrette DL, Yanosky J, Cascio WE. Acute adverse effects of fine particulate air pollution on ventricular repolarization. Environ Health Perspect. 2010 Jul; 118(7):1010-5.
|
|
|
|
|
10.
|
Stevenson RT, Patel PP, Davidson WR, Naccarelli GV, Wolbrette DL, Samii SM, Banchs JE, Penny-Peterson ED, Gonzalez MD. Supernormal conduction and linking in an accessory AV pathway. J Interv Card Electrophysiol. 2011 Jan; 30(1):27-30.
|
|
|
|
|
11.
|
Patel P, Banchs JE, Stevenson RT, Patel ND, Naccarelli GV, Wolbrette DL, Samii SM, Penny-Peterson ED, Gonzalez MD. Distal balloon occlusion allows epicardial lead placement in a tortuous branch of the great cardiac vein. J Interv Card Electrophysiol. 2009 Aug; 25(2):159-61.
|
|
|
|
|
12.
|
Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, Gonzalez MD, Naccarelli GV. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter. J Interv Card Electrophysiol. 2008 Nov; 23(2):111-5.
|
|
|
|
|
13.
|
Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs. 2008 May; 17(5):805-10.
|
|
|
|
|
14.
|
Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, Gonzalez MD. Vernakalant: pharmacology electrophysiology, safety and efficacy. Drugs Today (Barc). 2008 May; 44(5):325-9.
|
|
|
|
|
15.
|
Hong Y, Jin X, Mo J, Lin HM, Duan Y, Pu M, Wolbrette DL, Liao D. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality--results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med. 2007 Jul; 262(1):113-22.
|
|
|
|
|
16.
|
Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. New antiarrhythmic treatment of atrial fibrillation. Expert Rev Cardiovasc Ther. 2007 Jul; 5(4):707-14.
|
|
|
|
|
17.
|
Banchs JE, Wolbrette DL, Naccarelli GV, Gonzalez MD. Paroxysmal atrioventricular block following a ventricular premature beat. J Cardiovasc Electrophysiol. 2007 Feb; 18(2):230.
|
|
|
|
|
18.
|
Samii SM, Hynes BJ, Khan M, Wolbrette DL, Luck JC, Naccarelli GV. Selection of drugs in pursuit of rate control strategy. Prog Cardiovasc Dis. 2005 Sep-Oct; 48(2):146-52.
|
|
|
|
|
19.
|
Hynes BJ, Luck JC, Wolbrette DL, Khan M, Naccarelli GV. A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone. Future Cardiol. 2005 Mar; 1(2):135-44.
|
|
|
|
|
20.
|
Wolbrette DL. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death. Curr Cardiol Rep. 2004 Sep; 6(5):379-84.
|
|
|
|
|
21.
|
Bhatta L, Luck JC, Wolbrette DL, Naccarelli GV. Complications of biventricular pacing. Curr Opin Cardiol. 2004 Jan; 19(1):31-5.
|
|
|
|
|
22.
|
Naccarelli GV, Hynes BJ, Wolbrette DL, Bhatta L, Khan M, Samii S, Luck JC. Atrial fibrillation in heart failure: prognostic significance and management. J Cardiovasc Electrophysiol. 2003 Dec; 14(12 Suppl):S281-6.
|
|
|
|
|
23.
|
Naccarelli GV, Wolbrette DL, Bhatta L, Khan M, Hynes J, Samii S, Luck J. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J Interv Card Electrophysiol. 2003 Oct; 9(2):215-22.
|
|
|
|
|
24.
|
Wolbrette D. Treatment of arrhythmias during pregnancy. Curr Womens Health Rep. 2003 Apr; 3(2):135-9.
|
|
|
|
|
25.
|
Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003 Mar 20; 91(6A):15D-26D.
|
|
|
|
|
26.
|
Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003 Mar 20; 91(6A):39D-44D.
|
|
|
|
|
27.
|
Hynes BJ, Luck JC, Wolbrette DL, Bhatta L, Khan M, Samii S, Naccarelli GV. Atrial fibrillation in patients with heart failure. Curr Opin Cardiol. 2003 Jan; 18(1):32-8.
|
|
|
|
|
28.
|
Naccarelli GV, Hynes J, Wolbrette DL, Bhatta L, Khan M, Luck J. Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation. Curr Cardiol Rep. 2002 Sep; 4(5):418-25.
|
|
|
|
|
29.
|
Luck JC, Bhatta L, Artman SE, Wolbrette DL, Pantelloni MA, Naccarelli GV. Entrainment of ventricular tachycardia with a permanent biventricular pacemaker. J Interv Card Electrophysiol. 2002 Aug; 7(1):105-11.
|
|
|
|
|
30.
|
Wolbrette D. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep. 2002 Apr; 2(2):105-9.
|
|
|
|
|
31.
|
Wolbrette D, Naccarelli G, Curtis A, Lehmann M, Kadish A. Gender differences in arrhythmias. Clin Cardiol. 2002 Feb; 25(2):49-56.
|
|
|
|
|
32.
|
Naccarelli GV, Antzelevitch C, Wolbrette DL, Luck JC. The Brugada syndrome. Curr Opin Cardiol. 2002 Jan; 17(1):19-23.
|
|
|
|
|
33.
|
Luck JC, Wolbrette DL, Boehmer JP, Ulsh PJ, Silber D, Naccarelli GV. Biventricular pacing in congestive heart failure: a boost toward finer living. Curr Opin Cardiol. 2002 Jan; 17(1):96-101.
|
|
|
|
|
34.
|
Naccarelli GV, Wolbrette DL, Luck JC. Proarrhythmia. Med Clin North Am. 2001 Mar; 85(2):503-26, xii.
|
|
|
|
|
35.
|
Wolbrette DL, Naccarelli GV. Management of implantable cardioverter defibrillator patients: role of predischarge electrophysiologic testing and proper patient instruction before hospital discharge. Curr Opin Cardiol. 2001 Jan; 16(1):72-5.
|
|
|
|
|
36.
|
Wolbrette DL, Naccarelli GV. Emerging indications for permanent pacing. Curr Cardiol Rep. 2000 Jul; 2(4):353-60.
|
|
|
|
|
37.
|
Naccarelli GV, Dell'Orfano JT, Wolbrette DL, Patel HM, Luck JC. Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy. Am J Cardiol. 2000 May 25; 85(10A):36D-45D.
|
|
|
|
|
38.
|
Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC. Amiodarone: what have we learned from clinical trials? Clin Cardiol. 2000 Feb; 23(2):73-82.
|
|
|
|
|
39.
|
Naccarelli GV, Wolbrette DL, Patel HM, Luck JC. Amiodarone: clinical trials. Curr Opin Cardiol. 2000 Jan; 15(1):64-72.
|
|
|
|
|
40.
|
Dell'Orfano JT, Patel H, Wolbrette DL, Luck JC, Naccarelli GV. Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol. 1999 Mar 1; 83(5):788-90, A10.
|
|
|
|
|
41.
|
Naccarelli GV, Luck JC, Wolbrette DL, Pae WE, Weller-Moore R, Dell'Orfano JT, Patel HM, Boehmer JP. Pacing therapy for congestive heart failure: is it ready for prime time? Curr Opin Cardiol. 1999 Jan; 14(1):1-3.
|
|
|
|
|
42.
|
Wolbrette D, Patel H. Arrhythmias and women. Curr Opin Cardiol. 1999 Jan; 14(1):36-43.
|
|
|
|
|
43.
|
Dell'Orfano JT, Luck JC, Wolbrette DL, Patel H, Naccarelli GV. Drugs for conversion of atrial fibrillation. Am Fam Physician. 1998 Aug; 58(2):471-80.
|
|
|
|
|
44.
|
Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC. A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators. J Cardiovasc Electrophysiol. 1998 Aug; 9(8):864-91.
|
|
|
|
|
45.
|
Dougherty AH, Wolbrette D. Images in cardiovascular medicine. Implantable defibrillator generator migration. Circulation. 1994 Sep; 90(3):1557.
|
|
|
|
|
46.
|
Naccarelli GV, Dougherty AH, Wolbrette D, Wiggins S. A critical appraisal of the cardiac arrhythmia suppression trial (CAST). Appl Cardiopulm Pathophysiol. 1991; 4(1):9-16.
|
|
|
|